Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 17, Issue 11, Pages 1504-1513
Publisher
Oxford University Press (OUP)
Online
2015-10-14
DOI
10.1093/neuonc/nov104
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
- (2014) Walter Taal et al. LANCET ONCOLOGY
- Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?
- (2014) Q. G. D'Alessandris et al. NEURO-ONCOLOGY
- Implications of bevacizumab discontinuation in adults with recurrent glioblastoma
- (2014) Mark D. Anderson et al. NEURO-ONCOLOGY
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboplatin and bevacizumab for recurrent malignant glioma
- (2012) MACIEJ M. MRUGALA et al. Oncology Letters
- Bevacizumab and daily temozolomide for recurrent glioblastoma
- (2011) Annick Desjardins et al. CANCER
- Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
- (2011) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
- (2010) Jeffrey J. Raizer et al. CANCER
- Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
- (2010) Alessandra B. Francesconi et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- (2010) Patrick Y. Wen et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment With Bevacizumab Plus Carboplatin for Recurrent Malignant Glioma
- (2010) Eric M. Thompson et al. NEUROSURGERY
- Response Assessment in Neuro-Oncology
- (2010) Eudocia C. Quant et al. Current Oncology Reports
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
- (2008) Ashwatha Narayana et al. JOURNAL OF NEUROSURGERY
- Malignant Gliomas in Adults
- (2008) Patrick Y. Wen et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started